EP1261861A1 - Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting - Google Patents
Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clottingInfo
- Publication number
- EP1261861A1 EP1261861A1 EP01905800A EP01905800A EP1261861A1 EP 1261861 A1 EP1261861 A1 EP 1261861A1 EP 01905800 A EP01905800 A EP 01905800A EP 01905800 A EP01905800 A EP 01905800A EP 1261861 A1 EP1261861 A1 EP 1261861A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- reagent
- electrochemical sensor
- electrodes
- thrombin
- blood clotting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
Definitions
- Electrochemical sensor for determining blood coagulation a corresponding blood coagulation measurement system and a method for determining blood coagulation
- the invention relates to a sensor on a dry chemical basis for determining blood coagulation, which has at least 2 electrodes on an inert carrier, and a dry reagent.
- the invention also relates to a blood coagulation measuring system containing an electrochemical sensor and a current measuring device.
- the invention also relates to a method for determining blood coagulation using an electrochemical sensor.
- EP-B 0 441 222 describes a method and sensor electrode system for the electrochemical determination of an analyte or an oxidoreduetase.
- the patent discloses the role of a reducible substance as an electron carrier in the redox reaction of an analyte to be determined on an electrode.
- a typical analyte is glucose, lactate or redox enzyme, such as glucose dehydrogenase or lactate dehydrogenase.
- An electrochemical method for the determination of proteases and antiproteases is known from EP-B 0 018 002.
- a protease or antiprotease substrate made of an oligopeptide to which an aromatic or heterocyclic amine or polyamine is bound is used there.
- the enzyme to be determined cleaves the bond between the carboxy-terminal amino acid and the amine or polyamine and the amount of the released amine or polyamine is determined electrochemically.
- the determination of freely moving components of the blood coagulation cascade in solution is described here.
- the present invention provides an electrochemical sensor, a blood coagulation measuring system and a method for determining blood coagulation, as described in the independent patent claims. Preferred embodiments are specified in the dependent claims.
- the sensor according to the invention is an analysis element on a dry chemical basis.
- the sensor contains at least two electrodes, of which at least one electrode is a so-called working electrode. In a preferred embodiment, it does not contain a classic reference electrode, such as an Ag / AgCl reference electrode, but only at least one working and one counter electrode.
- the electrodes can be constructed from all common electrode materials, for example metals, noble metals, alloys or graphite, preferably from noble metals, such as gold or palladium, or graphite.
- the different electrodes of the sensor can consist of the same or different materials. In a particularly preferred embodiment, the sensor contains a working electrode and a counter electrode, both of which are made of palladium.
- the dry reagent of the sensor according to the invention contains, for example, the compound (I)
- thrombin substrate means arginine, pro proline and gly glycine; Tos corresponds to the amino protection group Tosyl.
- Arg means arginine, pro proline and gly glycine; Tos corresponds to the amino protection group Tosyl.
- all residues which can be split off from thrombin are possible as peptide residues of the thrombin substrate according to the invention, so that an electrochemically determinable phenylenediamine is released from the substrate.
- the enzyme thrombin is the last protease in the coagulation cascade and is only formed from the protein prothrombin in the course of blood coagulation. It is therefore possible to follow the clotting of the blood by measuring the enzyme activity of the thrombin and thus to determine the clotting time.
- a p-aminoaniline phenylenediamine
- EP-B 0 441 222 a p-aminoaniline (phenylenediamine) is formed, which is oxidized on the working electrode of the sensor, as described in EP-B 0 441 222.
- the released electrons are detected.
- all the compounds which are described as an electron transmitter (or mediator) of the second type in EP-B 0 441 222 can be used as the electrochemically detectable part of the thrombin substrate according to the invention.
- glucose-dye-oxidoreductase GlucDOR
- GlucDOR glucose-dye-oxidoreductase
- the primary oxidation product of the 2nd type electron transmitter is a quinodiimine, which can be recycled into p-aminoaniline using a dye oxidoreductase, such as glucose dye oxidoreductase (GlucDOR), and can thus again release electrons at the working electrode. A considerable amplification of the original signal is thus possible.
- a dye oxidoreductase such as glucose dye oxidoreductase (GlucDOR)
- GlucDOR glucose dye oxidoreductase
- GlucDOR glucose dye oxidoreductase
- special additional substrates corresponding to the glucose for GlucDOR
- alcohols for the enzyme alcohol dehydrogenase or lactate for Lactate oxidase are then optionally introduced into the reagent formulation in suitable amounts.
- the electrochemical determination of blood coagulation is preferably carried out quasi-potentiostatically, preferably with a 2-electrode system, in which one electrode is connected simultaneously as a reference and counter electrode, the other electrode as a working electrode. A constant voltage is applied to this 2-electrode system and the current is measured over time. This method is also known as the amperometric measuring method.
- the temporal course of the current is recorded and the time after which the measured current exceeds a predetermined threshold value from the start of the coagulation measurement. This period is a measure of the clotting time.
- voltametric measuring methods can also be used. In this case, no constant voltage is regulated between the electrodes, but the voltage is changed linearly from a start value to an end value and then returned to the start value. This process can be repeated several times over the entire measurement period.
- the current is plotted against the voltage and one then obtains nested current-voltage curves (cyclic voltamograms) in accordance with the repetitions.
- a suitable voltage range oxidation peaks and reduction peaks of the electron transmitter are shown in these curves.
- the height of these peaks is directly proportional to the concentration of the electron transmitter, unless other redox-active substances in the covered potential range are also oxidized or reduced and thus make an additional current contribution. Such a disturbance can possibly be neglected when measuring a change in concentration.
- X ⁇ , X 2 and X 3 represent natural or artificial amino acids including any protective groups.
- the sequence X ⁇ -X 2 -X 3 is depending on the desired
- amino acid sequences are in some cases also commercially available from various companies for recognizing different coagulation factors, for example from Pentapharm LTD, Basel, Switzerland or from Chromogenix Germany, Haemochrom Diagnostica GmbH, Essen, Germany.
- a molecular part X 4 -X 5 is linked to the amino acid sequence XX 2 -X 3 as a leaving group, which is split off by the proteolytic activity of the coagulation factor, for example thrombin.
- the part of the molecule X 4 -X 5 which is used for the detection of the proteolytic activity, is colored (for the photometric determination), depending on the desired detection principle, fluorescent (see among others MK Ramjee, Anal. Biochem., 277, 11-18 ( 2000)) or electroactive (see EP-B 0 018 002).
- the molecular part X 4 -X 5 is electroactive in the context of the present invention, that is to say can be implemented on an electrode with electron donation or electron absorption.
- X 4 -X 5 preferably has an oxidation potential of at most 350 mV against an Ag / AgCl electrode and can be detected by an electrochemical measurement.
- X 4 can be N or NH as the linking atom or group to the oligopeptide sequence.
- the molecular part Xs can have the following structure (III),
- R 1 and R 2 are independently alkyl, hydroxyalkyl, alkoxyalkyl, phosphoramidoalkyl, polyhydroxyalkyl, sulfonalkyl, or hydrogen
- R 3 and R 4 are OH, O-alkyl, alkyl, H, halogen
- NR ⁇ R 2 , C0 2 R, CONR 1 R 2 , SR b are NRi-CO-Rj, O-CO-Ri, H.
- X ? have the following structure (IV):
- X 5 can have the following structure (V):
- R 1 to R 3 have the meaning given above for formulas III and IV.
- the peptide substrate is a thrombin substrate of the general formula VI
- protease substrates are compounds which consist of a peptide residue which can be split off from a protease of the blood coagulation system and which is amidically bonded to substituted anilines, in particular to a phenylenediamine residue, via the carboxyl end.
- the global tests include in particular the following tests: PT (prothrombin time test), aPTT (activated partial prothrombin time test) and ACT (“activated clotting time” test).
- the invention is illustrated by the following examples. All examples have been described for whole blood as sample materials. However, the sensors and methods according to the invention are also suitable for citrate plasmas if calcium is added to the formulation of the test carrier or the sample. It is also possible according to the invention, in addition to the method of applying the reagent to the electrodes mentioned in the examples (activators and substrate are metered onto the electrodes together and then dried), the reagent not directly on the electrodes, but in the vicinity of the electrodes, for example next to the electrodes on a flat substrate, apply and dry. In this case, the reagent with the blood sample is transported to the electrodes during the measurement.
- the reagent in porous materials such as, for example, nonwovens, papers, membranes and the like, for example by releasably impregnating.
- the blood or plasma sample must flow through these materials before contact with the electrodes and thereby absorb the reagent.
- the electrochemical operation is quasi-potentiostatic as a 2-electrode
- a constant voltage is applied to this two-electrode system and the current measured over time.
- a soluble, reducible substance is used, which picks up electrons at the counter electrode and thus ensures the current transport through the counter electrode.
- the reduction potential of this substance and the constant voltage applied to the sensor between the working and counter electrodes limit the oxidation potential that can be achieved on the working electrode.
- the p-aminoaniline to be detected on the working electrode by oxidation must lie within the oxidation potential that can be achieved.
- the potential at the working electrode against a hypothetical silver-silver chloride reference electrode must be set in the described two-electrode system so that the current through the working electrode (here anode) and the current through the counter electrode (here cathode) are equal in amount.
- the reducible substance used must not be able to be oxidized at the same time on the working electrode within the maximum achievable oxidation potential, since otherwise the signal of the p-aminoaniline split off by the upstream enzymatic reaction is superimposed.
- a p-amino-anihn (phenylenediamine) is released from the thrombin substrate by the action of the opening cascade. This is oxidized on the working electrode and the electrodes released in the process are detected.
- the primary oxidation product is a quinodiimine.
- the glucose necessary for the "amplification enzyme" GlucDOR as a substrate is part of the sample (approx. 10 mM) and was therefore not incorporated into the recipe. However, glucose addition is possible in principle.
- test setup (sensor) used in this example corresponded to the sensor described in l.I.b) (use of a "mediator of the second type").
- ACT test was carried out on whole blood samples to which 1 to 6 U of heparin per ml were added (“heparin spike”) using the sensor described above. A potential of 300 mV was applied and the time was read at a threshold value of 0.5 ⁇ A. The results are shown in the following table:
- the hematocrit content can be measured using a special measurement algorithm and used to correct the current values.
- a short measurement of the impedance of the sensor wetted with blood is carried out before the actual chronoamperometric measurement.
- an alternating voltage with a frequency of 2 kHz and an amplitude of approximately 10 mV is applied between the working and counter electrodes and the resulting effective value of the alternating current flowing through the sensor is measured.
- the impedance Z of the sensor filled with the blood sample is obtained. This impedance Z is dependent on the temperature and the hematocrit content of the blood.
- the hematocrit content in the blood can be measured independently of the concentration of the actual electron transmitter (mediator).
- Z is the impedance of the current measurement and Z me d ⁇ a n is the impedance from the middle of many blood samples and is the result of a batch calibration.
- the compensation of the hematocrit effect was shown using the example of a PT test.
- the test setup used in this example corresponded to the setup described in Example 1 under Ib).
- the recipe used was identical to recipe 2 listed in Example 1 under II a).
- Fresh venous blood was cooled to 0 ° C on the ice bath. Aliquots were separated in a table centrifuge in erythrocytes and cell pellet. Higher hematocrits were adjusted by removing part of the plasma and resuspending the cells in the remaining plasma. Lower hematocrits were adjusted by adding plasma obtained from another aliquot of the same blood as described.
- voltametric measuring methods can also be used. There is no constant voltage between the electrodes, but the voltage is linear from one
- Start value changed to an end value and then moved back to the start value. This process is repeated several times over the entire measurement period.
- the current is then plotted against the voltage, and the current-voltage curves are then nested in accordance with the repetitions (cyclic voltamograms). With a suitable voltage range, oxidation peaks and reduction peaks of the electron carrier are shown in these curves.
- the primary point of interest is the point in time when the charging of a cyclic voltamogram begins to increase and how quickly this happens. That means, when does the clotting start (Thrombin is activated) and how fast does this run (how fast is how much thrombin is additionally activated). For this reason, as shown in FIG. 4, the time derivative is formed from the curves in FIG. 3, ie dQ to dt. The maximum of the slope is the maximum in the time derivative. The time t of the maximum can be read off as the clotting time.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10007910 | 2000-02-21 | ||
DE10007910 | 2000-02-21 | ||
US18405900P | 2000-02-22 | 2000-02-22 | |
US184059P | 2000-02-22 | ||
DE10016775A DE10016775A1 (en) | 2000-02-21 | 2000-04-04 | Electrochemical sensor for determining blood coagulation, a corresponding blood coagulation measurement system and a method for determining blood coagulation |
DE10016775 | 2000-04-04 | ||
PCT/EP2001/001848 WO2001063271A1 (en) | 2000-02-21 | 2001-02-19 | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1261861A1 true EP1261861A1 (en) | 2002-12-04 |
EP1261861B1 EP1261861B1 (en) | 2004-09-29 |
Family
ID=27213672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01905800A Expired - Lifetime EP1261861B1 (en) | 2000-02-21 | 2001-02-19 | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1261861B1 (en) |
JP (1) | JP2003524184A (en) |
AT (1) | ATE278186T1 (en) |
AU (1) | AU2001233785A1 (en) |
CA (1) | CA2400651A1 (en) |
WO (1) | WO2001063271A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
GB0316075D0 (en) * | 2003-07-09 | 2003-08-13 | Molecular Sensing Plc | Protease detection assay |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
SE0303249D0 (en) | 2003-12-02 | 2003-12-02 | Inst Polymerutveckling Ab | Hematocrit and analyte concentration determination |
WO2005065414A2 (en) | 2003-12-31 | 2005-07-21 | Pelikan Technologies, Inc. | Method and apparatus for improving fluidic flow and sample capture |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
FR2874385B1 (en) * | 2004-08-18 | 2006-12-08 | Biopep Sa | METHOD AND DEVICE FOR MEASURING ENZYMA ACTIVITY IN A BIOLOGICAL FLUID |
DE602005023433D1 (en) * | 2005-07-07 | 2010-10-21 | Asulab Sa | System for the differential determination of the amount of a proteolytic enzyme in a body fluid |
EP1918718A1 (en) * | 2006-10-31 | 2008-05-07 | Roche Diagnostics GmbH | Methods and devices for electrochemical determination of factor Xa inhibitors in blood samples |
TWI516601B (en) * | 2007-10-26 | 2016-01-11 | 環球生物醫療感測器私人有限公司 | Apparatus and method for electrochemical detection |
US8603768B2 (en) * | 2008-01-17 | 2013-12-10 | Lifescan, Inc. | System and method for measuring an analyte in a sample |
EP2265324B1 (en) | 2008-04-11 | 2015-01-28 | Sanofi-Aventis Deutschland GmbH | Integrated analyte measurement system |
EP2144061A1 (en) | 2008-07-11 | 2010-01-13 | F. Hoffmann-Roche AG | Continuous method for inline application of tensides on coated sensor film |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
EP2371284A1 (en) * | 2010-03-24 | 2011-10-05 | C A Casyso AG | Method and apparatus for determining at least one evaluation parameter of a blood sample |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP2395353B1 (en) * | 2010-06-09 | 2018-08-22 | Apex Biotechnology Corp. | Device and method for measuring prothrombin time and hematocrit by analyzing change in reactance in a sample |
DE102011006349A1 (en) * | 2011-03-29 | 2012-10-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Device and method for detecting, measuring and / or influencing the clotting of blood systems |
EP2524965A1 (en) * | 2011-05-16 | 2012-11-21 | The Swatch Group Research and Development Ltd. | Increase in storage lifetime of a thrombin sensor |
US10295555B2 (en) | 2013-12-25 | 2019-05-21 | Hitachi High-Technologies Corporation | Automatic analysis device and analysis method |
WO2015137356A1 (en) * | 2014-03-11 | 2015-09-17 | 大日本印刷株式会社 | Concentration detection method for microbial impurities, electrode chip, and oligopeptide |
CN105259227B (en) * | 2015-11-10 | 2017-10-17 | 华东交通大学 | A kind of blood coagulation enzyme assay method of molecular imprinting electrochemical sensor |
CN109073588A (en) * | 2016-02-16 | 2018-12-21 | 生化学工业株式会社 | Use the electrochemical gaging of phenylenediamine derivative |
CN113655099A (en) * | 2021-08-26 | 2021-11-16 | 中科质谱(天津)医疗科技有限公司 | Electrochemical sensor and application thereof in human body physiological and biochemical index detection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0018002B1 (en) * | 1979-04-24 | 1983-02-09 | Marcel Jozefonvicz | Process for the determination of proteases and antiproteases |
WO1998039643A1 (en) * | 1997-03-05 | 1998-09-11 | Diametrics | Method and apparatus for measurement of whole blood coagulation parameters |
EP1031830B8 (en) * | 1999-02-23 | 2009-12-09 | Asulab S.A. | Electrochemical system for the determination of blood coagulation time |
-
2001
- 2001-02-19 AT AT01905800T patent/ATE278186T1/en not_active IP Right Cessation
- 2001-02-19 AU AU2001233785A patent/AU2001233785A1/en not_active Abandoned
- 2001-02-19 JP JP2001562186A patent/JP2003524184A/en not_active Ceased
- 2001-02-19 CA CA002400651A patent/CA2400651A1/en not_active Abandoned
- 2001-02-19 EP EP01905800A patent/EP1261861B1/en not_active Expired - Lifetime
- 2001-02-19 WO PCT/EP2001/001848 patent/WO2001063271A1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
See references of WO0163271A1 * |
Also Published As
Publication number | Publication date |
---|---|
ATE278186T1 (en) | 2004-10-15 |
WO2001063271A1 (en) | 2001-08-30 |
JP2003524184A (en) | 2003-08-12 |
EP1261861B1 (en) | 2004-09-29 |
CA2400651A1 (en) | 2001-08-30 |
AU2001233785A1 (en) | 2001-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1261861B1 (en) | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting | |
EP2079849B1 (en) | Methods and apparatuses for electrochemical determination of factor xa inhibitors in blood samples | |
EP0018002B1 (en) | Process for the determination of proteases and antiproteases | |
DE60317422T2 (en) | Mediator stabilizing compound and methods of use for detection of electrochemical analytes | |
KR101854883B1 (en) | Apparatus and method for electrochemical detection | |
D O’Neill et al. | Comparisons of platinum, gold, palladium and glassy carbon as electrode materials in the design of biosensors for glutamate | |
DE69020908T2 (en) | REDOX MEDIATION REAGENT AND BIOSENSOR. | |
DE3805773A1 (en) | ENZYME ELECTRODE SENSORS | |
AU2011354498B2 (en) | Proteolysis detection | |
WO2000050446A1 (en) | Oligopeptide derivatives for the electrochemical measurement of protease activity | |
Zen et al. | Voltammetric determination of serotonin in human blood using a chemically modified electrode | |
US20030146113A1 (en) | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting | |
US5395493A (en) | Method for determination of peracids | |
Hahn et al. | The development of new microelectrode gas sensors: an odyssey. Part 1. O2 and CO2 reduction at unshielded gold microdisc electrodes | |
DE10016775A1 (en) | Electrochemical sensor for determining blood coagulation, a corresponding blood coagulation measurement system and a method for determining blood coagulation | |
Zhu et al. | 9, 10‐Anthraquinone Modified Glassy Carbon Electrode and Its Application for Hemoglobin Determination | |
EP0972203A1 (en) | REAGENT FOR DETERMINING aPTT | |
EP2486145B1 (en) | Method of determining factor XIII with the aid of plasma-based reference material. | |
Takayama et al. | Mediated amperometric biosensor for nicotinic acid based on whole cells of Pseudomonas fluorescens | |
JPS5935598B2 (en) | Method for measuring protease and anti-protease | |
Carelli et al. | Determination of Cytochrome C, in Solution and in The Adsorbed State, by Differential Pulse Voltammetry (DPV). | |
DE4216980A1 (en) | Blood group determn. using immuno-sensor - based on electrochemical or piezoelectric transducer coated with specific binding reagents | |
DE19619056C2 (en) | Method and sensor for the enzymatic-electrochemical determination of substrates NAD · + · - and NAD (P) · + · -dependent dehydrogenases | |
JPS63139244A (en) | Glucose sensor | |
EP1066406B1 (en) | Detection of proteinases by means of an enzyme as proteinase substrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020923 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: F. HOFFMANN-LA ROCHE AG Owner name: ROCHE DIAGNOSTICS GMBH |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: F. HOFFMANN-LA ROCHE AG Owner name: ROCHE DIAGNOSTICS GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20040929 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 Ref country code: GB Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040929 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50103875 Country of ref document: DE Date of ref document: 20041104 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041229 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041229 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050219 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050219 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050228 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20050228 Year of fee payment: 5 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20040929 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
GBV | Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed] |
Effective date: 20040929 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
BERE | Be: lapsed |
Owner name: F. HOFFMANN-LA ROCHE A.G. Effective date: 20050228 Owner name: ROCHE DIAGNOSTICS G.M.B.H. Effective date: 20050228 |
|
26N | No opposition filed |
Effective date: 20050630 |
|
EN | Fr: translation not filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060901 |
|
BERE | Be: lapsed |
Owner name: F. *HOFFMANN-LA ROCHE A.G. Effective date: 20050228 Owner name: *ROCHE DIAGNOSTICS G.M.B.H. Effective date: 20050228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050228 |